RxDoctor Payments Data

Fallon Etkin, PA

Physician Assistant · Halfmoon, NYNPI 1871101501

Payments from drug & device makers

$4,046in general payments, 2019–2025

Across 177 payments — averaging $22.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$794
  • GSK$377
  • Lilly USA, LLC$334
  • Abbott$222
  • Astellas Pharma US Inc$218
  • plus $1K from 24 others

What the payments were for

  • Food & beverage$3,98098%
  • Education$662%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,046 in reported general payments places this provider in the 90th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$37,689
Medicare patients
163
Services billed
940

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide21$33,963
RybelsusSemaglutide11$18,624
FarxigaDapagliflozin Propanediol12$15,036
Albuterol Sulfate HfaAlbuterol Sulfate62$1,680
Atorvastatin Calcium86$920
Rosuvastatin Calcium46$863
Levothyroxine Sodium60$724
Fluticasone Propionate18$675
Duloxetine Hcl18$663
Omeprazole43$533
Chlorthalidone14$427
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav32$404
Simvastatin14$321
Doxycycline Hyclate21$267
Lisinopril47$262

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,024$52,58732 claims
AstraZenecaFarxiga$80$15,03612 claims
PfizerPaxlovid$72$018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Halfmoon

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →